12 / 48 wk Pivotal PFT vs PBO in COPD II
Public ClinicalTrials.gov record NCT00782509. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 mcg [2 Actuations of 2.5 mcg] and 10 mcg [2 Actuations of 5 mcg]) Delivered by the Respimat® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).
Study identification
- NCT ID
- NCT00782509
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 644 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2009 (Type not available)
- Primary completion
- Sep 2010 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 27, 2014
Started 2009
United States locations
- U.S. sites
- 28
- U.S. states
- 18
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1222.12.1227 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 1222.12.1218 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1222.12.1226 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1222.12.1214 Boehringer Ingelheim Investigational Site | Waterbury | Connecticut | — | — |
| 1222.12.1207 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1222.12.1224 Boehringer Ingelheim Investigational Site | Panama City | Florida | — | — |
| 1222.12.1222 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1222.12.1208 Boehringer Ingelheim Investigational Site | Winter Park | Florida | — | — |
| 1222.12.1220 Boehringer Ingelheim Investigational Site | River Forest | Illinois | — | — |
| 1222.12.1229 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 1222.12.1219 Boehringer Ingelheim Investigational Site | Ann Arbor | Michigan | — | — |
| 1222.12.1209 Boehringer Ingelheim Investigational Site | Livonia | Michigan | — | — |
| 1222.12.1233 Boehringer Ingelheim Investigational Site | Henderson | Nevada | — | — |
| 1222.12.1228 Boehringer Ingelheim Investigational Site | Summit | New Jersey | — | — |
| 1222.12.1206 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 1222.12.1205 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 1222.12.1213 Boehringer Ingelheim Investigational Site | Elizabeth City | North Carolina | — | — |
| 1222.12.1223 Boehringer Ingelheim Investigational Site | Harrisburg | North Carolina | — | — |
| 1222.12.1217 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1222.12.1203 Boehringer Ingelheim Investigational Site | Cincinnatti | Ohio | — | — |
| 1222.12.1201 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1222.12.1230 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 1222.12.1216 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1222.12.1221 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1222.12.1212 Boehringer Ingelheim Investigational Site | Danville | Virginia | — | — |
| 1222.12.1211 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1222.12.1225 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1222.12.1232 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00782509, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2014 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00782509 live on ClinicalTrials.gov.